At the time of writing, Catalyst Pharmaceuticals Inc [CPRX] stock is trading at $22.34, up 1.87%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The CPRX shares have gain 5.63% over the last week, with a monthly amount glided 2.62%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Catalyst Pharmaceuticals Inc [NASDAQ: CPRX] stock has seen the most recent analyst activity on November 18, 2024, when Stephens initiated its Overweight rating and assigned the stock a price target of $35. Previously, Citigroup started tracking the stock with Buy rating on March 14, 2024, and set its price target to $27. On March 07, 2024, BofA Securities initiated with a Buy rating and assigned a price target of $23 on the stock. Oppenheimer started tracking the stock assigning a Outperform rating and suggested a price target of $30 on December 21, 2023. ROTH Capital downgraded its rating to a Neutral and raised its price target to $15.50 on August 24, 2022.
For the past year, the stock price of Catalyst Pharmaceuticals Inc fluctuated between $13.00 and $24.27. Currently, Wall Street analysts expect the stock to reach $19.38 within the next 12 months. Catalyst Pharmaceuticals Inc [NASDAQ: CPRX] shares were valued at $22.34 at the most recent close of the market. An investor can expect a potential drop of -13.25% based on the average CPRX price forecast.
Analyzing the CPRX fundamentals
According to Catalyst Pharmaceuticals Inc [NASDAQ:CPRX], the company’s sales were 460.48M for trailing twelve months, which represents an 25.33% jump. Gross Profit Margin for this corporation currently stands at 0.82% with Operating Profit Margin at 0.38%, Pretax Profit Margin comes in at 0.41%, and Net Profit Margin reading is 0.31%. To continue investigating profitability, this company’s Return on Assets is posted at 0.18, Equity is 0.26 and Total Capital is 0.26. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 21.64 points at the first support level, and at 20.94 for the second support level. However, for the 1st resistance point, the stock is sitting at 23.03, and for the 2nd resistance point, it is at 23.72.
Ratios To Look Out For
It is important to note that Catalyst Pharmaceuticals Inc [NASDAQ:CPRX] has a current ratio of 5.11. As well, the Quick Ratio is 4.92, while the Cash Ratio is 4.2. Considering the valuation of this stock, the price to sales ratio is 5.89, the price to book ratio is 4.03 and price to earnings (TTM) ratio is 19.06.
Transactions by insiders
Recent insider trading involved INGENITO GARY, Officer, that happened on Nov 27 ’24 when 12000.0 shares were purchased. Director, Harper Molly completed a deal on Nov 27 ’24 to buy 17500.0 shares. Meanwhile, Officer Elsbernd Brian bought 13256.0 shares on Nov 26 ’24.
